Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Thammasat University
Acute kidney injury (AKI)occur 7.7-42% after cardiac surgery. The incidence of AKI requiring renal replacement therapy following coronary artery bypass grafting (CABG) surgery was 0.7-3.5% and increase mortality rate. Erythropoietin (EPO) is now considered a novel anti-apoptotic and anti-inflammatory action. The present study was designed to evaluate the administration of EPO as a means of preventing AKI in these patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
age \> 18 years.
serum creatinine levels \> 1.2 mg/dL and baseline creatinine clearance levels \< 60 mL/min (as measured in their most recent sample,drawn within 2 months prior to the beginning of the study)
patients who need cardiac surgery
You may not be if
patients with acute kidney injury
end stage renal disease (requiring dialysis)
unstable renal function (as evidenced by a change in serum creatinine of \> 0.5 mg/dL, or \> 25%, within 14 days prior to the study)
allergy to any of erythropoietin
suffered from congestive heart failure, cardiogenic shock or emergent cardiac surgery.
receiving erythropoietin within 14 days before the study
